Cancer biomarkers have transformed current practices in the oncology clinic. Continued
discovery and validation are crucial for improving early diagnosis, risk stratification, and …

Tumor tissue processing methodologies in combination with data‐independent acquisition
mass spectrometry (DIA‐MS) have emerged that can comprehensively analyze the …

Although the field of mass spectrometry-based proteomics is still in its infancy, recent
developments in targeted proteomic techniques have left the field poised to impact the …

Availability of a suite of biomarkers for early detection, stratification into distinct subtypes,
and monitoring progression or response to therapy promises significant improvements in …

Mass spectrometry (MS)-based proteomics have been increasingly implemented in various
disciplines of laboratory medicine to identify and quantify biomolecules in a variety of …

Cancer genomics research aims to advance personalized oncology by finding and targeting
specific genetic alterations associated with cancers. In genome-driven oncology, treatments …

Cancer presents high mortality and morbidity globally, largely due to its complex and
heterogenous nature, and lack of biomarkers for early diagnosis. A proteomics study of …

The utility of mass spectrometry (MS)-based proteomic analyses and their clinical
applications have been increasingly recognized over the past decade due to their high …

MS is an important analytical tool in clinical proteomics, primarily in the disease‐specific
discovery, identification and characterisation of proteomic biomarkers and patterns. MS …

There is a critical need for the discovery of novel biomarkers for early detection and targeted
therapy of cancer, a major cause of deaths worldwide. In this respect, proteomic …